Tracking Valuations, page-4

If the trial replicates the results of the (very small sample size) compassionate trial - then my view is MSB actually becomes priceless. I actually think MSB needs to look at this from an entirely new paradigm in terms of pricing.

Let's look at a few facts. The current market capitalisation of MSB is $1.73 billion AUD.

The Australian government alone has spent $193 billion in its response to Covid 19.

One estimate I read from the Centre for Strategic and International Studies was that the G20 have spent $5 trillion on Covid 19 mitigation - and I think that figure is USD.

https://www.csis.org/analysis/breaking-down-g20-covid-19-fiscal-response

A replication of the compassionate trial reduces the lethality of Covid 19 to something approximating seasonal influenza. This is a condition we accept as a society and the presence of it still allows society to function as per normal.

If the trial is successful we have the key that can unlock society and obliterate massive ongoing government spending.

Even at only 1% of the $5 trillion mitigation spent by the G20 alone equates to $50 billion dollars.

This treatment potentially offers governments the ability to reopen the economies of their countries, even if MSB offered this service not as a per person treatment cost, but as a single fee to the government of each country, and that fee was capped at 1% of their Covid 19 mitigation - the potential profit is as eye watering as the saving to each of those countries this treatment would bring, and don't forget the lives that can be saved.